ORP-101 is a new chemical entity designed with intent to create a large stable molecule and to confer partial μ agonist and full κ-antagonist receptor pharmacology.
- FDA Fast Track designation for IBS-D
- No opioid-like CNS effects
- Safe and well tolerated in Phase 1 studies
- Phase 2 IBS-D study nearing end of enrollment, having successfully passed two interim data analyses
- Exploring additional indications for post-IBD IBS and pancreatic pain